Your provider will review your weight history, metabolic health, medications, past use of semaglutide or tirzepatide, lab history, side effect history, lifestyle, and goals
The primary mechanisms of action include: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner, which helps lower blood glucose levels without causing hypoglycaemia when used alone Suppressing glucagon release from pancreatic alpha cells, reducing hepatic glucose production Slowing gastric emptying , which prolongs the feeling of fullness after meals Acting on appetite centres in the brain , particularly the hypothalamus, to reduce hunger and food intake GLP-1 receptor agonists are typically administered via subcutaneous injection, with dosing frequencies ranging from once daily to once weekly depending on the specific medication, though oral semaglutide (Rybelsus) is also available
20 BellGISanchez-PescadorRLaybournPJNajarianRC
Federal vs State Regulations: Federal Rules Apply Everywhere: Semaglutide requires prescription from licensed provider Provider must conduct appropriate medical evaluation Pharmacies must be properly licensed and registered For compounded semaglutide: must be on FDA shortage list State Rules Vary: Telemedicine Prescribing: Some states allow prescribing after video/phone consultation only Others permit asynchronous (message-based) prescribing A few require initial in-person visit before telemedicine Provider must hold active license in patients state Pharmacy Regulations: Interstate pharmacy compacts allow some reciprocal licensing Some states require in-state pharmacy licensing to ship there Compounding regulations vary by state Some states have stricter oversight than others States with Fewest Restrictions: These states generally have more permissive telemedicine and compounding regulations: Texas Florida California Arizona Colorado Tennessee Georgia North Carolina Nevada Utah Most telehealth providers serve these states with minimal additional requirements
Canada has roughly 8,700 new thyroid cancer cases annually, with medullary thyroid cancer representing only 2-4% of these
Some practitioners do prescribe phentermine alongside GLP-1 receptor agonists
